Bank OZK Has $360,000 Stock Holdings in Novo Nordisk A/S $NVO

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

Bank OZK lessened its stake in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 75.9% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 5,182 shares of the company's stock after selling 16,331 shares during the period. Bank OZK's holdings in Novo Nordisk A/S were worth $360,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Copeland Capital Management LLC grew its holdings in Novo Nordisk A/S by 184.8% during the first quarter. Copeland Capital Management LLC now owns 393 shares of the company's stock valued at $27,000 after purchasing an additional 255 shares during the last quarter. North Capital Inc. acquired a new position in Novo Nordisk A/S during the first quarter valued at approximately $27,000. Park Square Financial Group LLC acquired a new position in Novo Nordisk A/S during the fourth quarter valued at approximately $29,000. Stone House Investment Management LLC acquired a new position in Novo Nordisk A/S during the first quarter valued at approximately $30,000. Finally, Transce3nd LLC acquired a new position in Novo Nordisk A/S during the fourth quarter valued at approximately $33,000. Institutional investors and hedge funds own 11.54% of the company's stock.

Wall Street Analyst Weigh In

Several equities analysts have commented on the company. UBS Group downgraded Novo Nordisk A/S from a "buy" rating to a "neutral" rating in a report on Tuesday, August 5th. BNP Paribas upgraded shares of Novo Nordisk A/S from an "underperform" rating to a "neutral" rating in a research note on Wednesday, August 13th. Dbs Bank downgraded shares of Novo Nordisk A/S to a "sell" rating in a research note on Friday, April 25th. HSBC cut Novo Nordisk A/S from a "buy" rating to a "hold" rating and set a $57.00 target price for the company. in a research report on Thursday, July 31st. Finally, Hsbc Global Res cut Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a research report on Thursday, July 31st. One research analyst has rated the stock with a sell rating, twelve have issued a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Hold" and an average price target of $83.75.

Novo Nordisk A/S Stock Up 2.7%

Shares of NYSE NVO opened at $53.81 on Tuesday. The stock has a market cap of $240.26 billion, a PE ratio of 14.78, a PEG ratio of 1.80 and a beta of 0.63. The business has a fifty day moving average of $64.52 and a two-hundred day moving average of $70.02. Novo Nordisk A/S has a 52-week low of $45.05 and a 52-week high of $139.74. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.56 and a current ratio of 0.78.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last announced its earnings results on Wednesday, August 6th. The company reported $0.97 earnings per share for the quarter, beating analysts' consensus estimates of $0.93 by $0.04. Novo Nordisk A/S had a return on equity of 78.64% and a net margin of 35.60%. The company had revenue of $11.69 billion during the quarter, compared to analyst estimates of $77.51 billion. As a group, equities research analysts expect that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Cuts Dividend

The firm also recently announced a semi-annual dividend, which will be paid on Tuesday, August 26th. Stockholders of record on Monday, August 18th will be paid a $0.4119 dividend. The ex-dividend date is Monday, August 18th. This represents a dividend yield of 240.0%. Novo Nordisk A/S's dividend payout ratio (DPR) is 45.05%.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.